Jazz Pharmaceuticals plc
Jazz Pharmaceuticals to Acquire Chimerix for $935 Million
Summary
On March 4, 2025, Jazz Pharmaceuticals Public Limited Company announced its entry into a definitive Agreement and Plan of Merger with Chimerix, Inc., a Delaware corporation, to acquire all outstanding shares of Chimerix's common stock at $8.55 per share in cash, representing a total consideration of approximately $935 million. The acquisition is subject to customary closing conditions, including regulatory approvals and the tender of a majority of Chimerix's voting common stock. The transaction aims to add a near-term commercial opportunity to Jazz's oncology portfolio with Chimerix's lead clinical asset, dordaviprone, a novel treatment for H3 K27M-mutant diffuse glioma, a rare, high-grade brain tumor with no approved therapies. The acquisition is expected to close in the second quarter of 2025, subject to regulatory approvals and other customary closing conditions. A joint press release announcing the transaction was issued on March 5, 2025.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement